Table 5. HRQOL composites and subscores comparing each of the four most frequently used DMDs against no DMD use.
| HRQOL composite/subscore | DMD used | n = | Mean HRQOL | SD | P | Pairwise comparisons* |
| Physical health composite | 1. Natalizumab only | 107 | 54.9 | 20.9 | 0.002 | 3 vs 1, P = 0.001 |
| 2. Fingolimod only | 71 | 55.8 | 20.5 | 3 vs 2, P = 0.012 | ||
| 3. Glatiramer only | 408 | 62.8 | 20.8 | 3 vs 4, P = 0.014 | ||
| 4. Interferons only | 351 | 59.0 | 20.7 | 3 vs 5, P = 0.003 | ||
| 5. No DMD | 919 | 59.0 | 22.1 | |||
| Mental health composite | 1. Natalizumab only | 118 | 64.5 | 21.4 | 0.012 | 5 vs 2, P = 0.027 |
| 2. Fingolimod only | 85 | 62.9 | 20.6 | 5 vs 4, P = 0.007 | ||
| 3. Glatiramer only | 450 | 67.8 | 21.7 | 3 vs 4, P = 0.045 | ||
| 4. Interferons only | 384 | 64.8 | 21.7 | |||
| 5. No DMD | 1078 | 68.2 | 21.0 | |||
| Physical health subscore | 1.Natalizumab only | 122 | 56.6 | 32.7 | < 0.001 | 3 vs 1, P < 0.001 |
| 2. Fingolimod only | 86 | 55.8 | 33.6 | 3 vs 2, P = 0.001 | ||
| 3. Glatiramer only | 463 | 68.6 | 30.0 | 3 vs 4, P = 0.013 | ||
| 4. Interferons only | 401 | 63.1 | 30.5 | 3 vs 5, P < 0.001 | ||
| 5. No DMD | 1125 | 56.4 | 34.9 | 4 vs 5, P < 0.001 | ||
| Role limitations physical subscore | 1. Natalizumab only | 119 | 43.1 | 43.8 | 0.023 | 3 vs 1, P = 0.044 |
| 2. Fingolimod only | 86 | 44.2 | 42.1 | 3 vs 4, P = 0.034 | ||
| 3. Glatiramer only | 463 | 52.0 | 43.8 | 3 vs 5, P = 0.001 | ||
| 4. Interferons only | 400 | 45.8 | 43.1 | |||
| 5. No DMD | 1123 | 44.3 | 43.3 | |||
| Pain subscore | 1. Natalizumab only | 121 | 70.4 | 27.9 | 0.003 | 3 vs 2, P = 0.001 |
| 2. Fingolimod only | 85 | 65.6 | 27.4 | 3 vs 4, P = 0.003 | ||
| 3. Glatiramer only | 463 | 75.5 | 24.8 | 3 vs 5, P = 0.017 | ||
| 4. Interferons only | 397 | 70.1 | 26.2 | 2 vs 5, P = 0.029 | ||
| 5. No DMD | 1129 | 72.0 | 26.2 | |||
| Emotional wellbeing subscore | 1. Natalizumab only | 122 | 67.1 | 19.4 | 0.006 | 4 vs 5, P < 0.001 |
| 2. Fingolimod only | 86 | 67.6 | 18.7 | |||
| 3. Glatiramer only | 464 | 68.6 | 19.0 | |||
| 4. Interferons only | 402 | 66.3 | 19.0 | |||
| 5. No DMD | 1132 | 70.1 | 18.2 | |||
| Health perception subscore | 1. Natalizumab only | 122 | 54.8 | 23.5 | 0.017 | 3 vs 2, P = 0.005 |
| 2. Fingolimod only | 86 | 50.3 | 19.3 | 3 vs 4, P = 0.047 | ||
| 3. Glatiramer only | 464 | 57.8 | 22.3 | 5 vs 2, P = 0.007 | ||
| 4. Interferons only | 401 | 54.7 | 21.4 | |||
| 5. No DMD | 1130 | 57.2 | 23.4 | |||
| Social function subscore | 1. Natalizumab only | 117 | 66.7 | 22.8 | 0.005 | 3 vs 1, P = 0.006 |
| 2. Fingolimod only | 83 | 68.1 | 22.6 | 3 vs 4, P = 0.008 | ||
| 3. Glatiramer only | 455 | 73.6 | 22.6 | 3 vs 5, P = 0.001 | ||
| 4. Interferons only | 388 | 69.1 | 24.0 | |||
| 5. No DMD | 1094 | 69.0 | 24.9 | |||
| Cognitive function subscore | 1.Natalizumab only | 122 | 63.4 | 27.9 | 0.008 | 5 vs 2, P = 0.004 |
| 2. Fingolimod only | 86 | 59.5 | 29.1 | 5 vs 4, P = 0.038 | ||
| 3. Glatiramer only | 464 | 65.5 | 27.2 | |||
| 4. Interferons only | 402 | 65.0 | 27.2 | |||
| 5. No DMD | 1132 | 68.2 | 26.3 | |||
| Health distress subscore | 1.Natalizumab only | 122 | 56.8 | 28.0 | 0.033 | 4 vs 5, P = 0.027 |
| 2. Fingolimod only | 86 | 55.6 | 27.5 | |||
| 3. Glatiramer only | 464 | 61.0 | 27.6 | |||
| 4. Interferons only | 402 | 58.3 | 26.8 | |||
| 5. No DMD | 1130 | 61.8 | 27.0 | |||
| Sexual function subscore | 1. Natalizumab only | 113 | 64.2 | 31.5 | 0.033 | 3 vs 2, P = 0.035 |
| 2. Fingolimod only | 74 | 62.4 | 29.2 | 3 vs 4, P = 0.039 | ||
| 3. Glatiramer only | 422 | 70.5 | 29.4 | 3 vs 5, P = 0.004 | ||
| 4. Interferons only | 369 | 66.0 | 30.2 | |||
| 5. No DMD | 976 | 65.4 | 31.3 |
Only domains with significant differences are shown.
HRQOL: health-related quality of life; DMD: disease-modifying drug.
*
Pairwise comparison with bonferroni adjustment applied, significant differences only shown. Bold denotes statistically significant.